Abstract. With 
Both groups showed no significant differences in the results of the clinical examination and in the degree of their mental and psychomotoric development at the time of study. We found the mean birth weight of the infants in group I significantly lower than in group II(3165\m=+-\339 vs 3666\m=+-\670 g, p<0.03). The individual birth weights, however, were normal for gestational age. The body weight difference between groups disappeared during the further somatic development of the children. The serum concentration of free thyroxine in group I was significantly higher than in group II (17.2 \ m=+-\ 2.4 vs 14.9\m=+-\1. 9 pmol/l, p<0.003), but fell in both groups within the normal range. The evaluation of the psychomotoric and intellectual capacity of the children at different developmental stages showed no abnormalities detectable by our tests. Thus, in the children of the two groups we found no adverse effects of a maternal antithyroid drug treatment during pregnancy or of inactive maternal Graves' disease alone, neither on thyroid gland size and function nor on the physical or intellectual development, after the neonatal period.
A pregnancy complicated by hyperthyroidism is not a rare event. Its prevalence has been estimated from 0.02-3.0% of all pregnancies (1, 2) . Severe hy¬ perthyroidism in a pregnant woman is an absolute indication for therapy. Today, the treatment with antithyroid drugs during pregnancy is widely ac¬ cepted and regarded as the treatment of choice (1, 3) . Only in the presence of a massive goitre caus¬ ing mechanical obstructions, when medical treat¬ ment is complicated by allergic-toxic reactions, or in the case of lack of patient compliance, surgical treatment may become necessary (4) .
There is a known risk for fetal malformation at¬ tributed to antithyroid drug treatment during pregnancy. Malformations of the earlobe, ompha¬ locele, and aplasia cutis congenita have been de¬ scribed after maternal antithyroid treatment (5) (6) (7) (8) (9) . Nevertheless it has been shown that untreated hy¬ perthyroidism in pregnancy is associated with an even higher rate of congenital malformations (8) .
Most studies of children born to mothers with Graves' disease, either receiving antithyroid drug therapy during pregnancy or being euthyroid with-out specific therapy, are limited to the neonatal period or have only compared serum concentra¬ tions of thyroid hormones (8, 10 (11) . Birth length and birth weight were compared with the 10th-90th percentile values of the Bayerische Neugeborenenstudie (12 (19, 20) , and the Standard Progressive Matrices/SPM (18 years and older) (21, 22) .
Statistical methods
Groups were compared using the Mann-Whitney U-test (23) . All values are given as mean ± standard deviation.
Results
The two groups of children did not differ signifi¬ cantly as to the results of the clinical and psycho¬ motoric examination at the time of study. The birth weight of the children in group I was significantly lower (p<0.03) than in group II, although gestational ages were not different. In the children of (Fig. la and lb) . Compared with published reference ranges (24) (25) (26) (27) (28) the chil¬ dren had a thyroid gland of normal size for sex and age. None of the children had any of the malfor¬ mations reported previously (8) .
Discussion
The aim of our study was to investigate whether Graves' disease in a pregnant woman affects thy¬ roid function, somatic and intellectual develop¬ ment of the offspring, and whether this adverse effect extends beyond the neonatal period. We compared children of mothers being sponta¬ neously euthyroid or euthyroid by antithyroid drug treatment.
Two children, both belonging to group I, had a euthyroid neonatal goitre and were treated with L-thyroxine in the postpartum period. Their mothers had been treated with thiamazole and car¬ bimazole, respectively. Neonatal goitre has been re¬ ported previously after maternal thionamide ther¬ apy, in most instances associated with hypothyroidism of the newborn (29, 30) . A goitre combined with a neonatal hyperthyroid metabolic state is fre¬ quently seen in association with placental transfer of maternal antibodies stimulating fetal thyroid growth and function (31, 32) . A hyperthyroid goitre was not seen in any of our patients. Since thyroid hormone and TSH concentrations were not measured routinely in clinically euthyroid neonates, we cannot exclude the presence of tran¬ sient, compensated hypothyroidism in children of treated mothers during the neonatal period.
Although 9 of 17 fetuses were exposed to anti¬ thyroid drugs in utero during the first trimester, none of the children of group I nor of group II showed any of the reported malformations. The rate of malformations has been found to be 1.7% in newborns after maternal methimazole therapy and up to 6% in newborns after untreated maternal hyperthyroidism during pregnancy (8) .
Birth weight was significantly lower in the chil¬ dren of group I, although the mean gestational age in both groups did not differ. All the children had a normal birth weight for their gestational age. A lower birth weight has been reported in children of mothers with untreated hyperthyroidism com¬ pared with those born to healthy mothers (33) . In another study a lower birth weight has also been found in children from carbimazole-treated women when compared with those of normal healthy pregnant women (2) . This is not necessarily due to antithyroid drug treatment, but might result from insufficient control of hyperthyroidism.
However 
